| Title |
Quetiapine versus other atypical antipsychotics for schizophrenia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, November 2013
|
| DOI | 10.1002/14651858.cd006625.pub3 |
| Pubmed ID | |
| Authors |
Laila Asmal, Srnka J Flegar, Jikun Wang, Christine Rummel‐Kluge, Katja Komossa, Stefan Leucht |
| Abstract |
In many countries, second-generation ('atypical') antipsychotic drugs have become the first-line drug treatment for people with schizophrenia. It is not clear how the effects of the various second-generation antipsychotic drugs differ. |
X Demographics
The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 5 | 14% |
| United States | 5 | 14% |
| United Kingdom | 2 | 6% |
| Nigeria | 1 | 3% |
| Ecuador | 1 | 3% |
| Austria | 1 | 3% |
| Curaçao | 1 | 3% |
| Unknown | 19 | 54% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 27 | 77% |
| Practitioners (doctors, other healthcare professionals) | 4 | 11% |
| Scientists | 3 | 9% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 324 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| Chile | 1 | <1% |
| Uruguay | 1 | <1% |
| Brazil | 1 | <1% |
| United Kingdom | 1 | <1% |
| Canada | 1 | <1% |
| Japan | 1 | <1% |
| Unknown | 317 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 47 | 15% |
| Researcher | 45 | 14% |
| Student > Bachelor | 37 | 11% |
| Student > Ph. D. Student | 27 | 8% |
| Student > Postgraduate | 22 | 7% |
| Other | 58 | 18% |
| Unknown | 88 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 106 | 33% |
| Psychology | 27 | 8% |
| Nursing and Health Professions | 22 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 20 | 6% |
| Neuroscience | 19 | 6% |
| Other | 31 | 10% |
| Unknown | 99 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2023.
All research outputs
#1,089,105
of 25,595,500 outputs
Outputs from Cochrane database of systematic reviews
#2,217
of 13,156 outputs
Outputs of similar age
#11,308
of 316,803 outputs
Outputs of similar age from Cochrane database of systematic reviews
#44
of 248 outputs
Altmetric has tracked 25,595,500 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,156 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,803 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 248 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.